Melanoma is an attractive target for CDK4/6 inhibitors (CDK4/6i) as the p16INK4a/Cyclin D1-CDK4/6/RB pathway is dysregulated in a majority of melanomas, while mutations causing loss or dysfunction of RB itself are uncommon6,7. Here, CDK4 is linked to melanoma.